• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Japan approves Novocure’s Optune brain cancer treatment

December 19, 2016 By Sarah Faulkner

Japan approves Novocure's Optune brain cancer treatmentNovocure (NSDQ:NVCR) said today that the Japanese Ministry of Health, Labor and Welfare has approved its tumor treating fields delivery system, Optune, for adult patients with supra-tentorial glioblastoma following surgery and radiation therapy.

The St. Helier, N.J.-based company is expected to submit an application for public reimbursement of the device in Japan for newly diagnosed GBM.

“The Japanese MHLW’s approval of Optune represents an important milestone for Novocure, enabling us to treat more patients who suffer from this aggressive disease,” CEO Asaf Danziger said in prepared remarks. “Optune in combination with temozolomide has been clinically proven to extend survival in patients with newly diagnosed GBM, and we look forward to making Optune available to newly diagnosed GBM patients in Japan.”

The company’s TTFields are low-intensity, alternating electric fields meant to inhibit cancer cell replication and cause cell death. The Japanese ministry’s approval was supported by Novocure’s phase III EF-14 trial, which evaluated Optune paired with temozolomide versus just temozolomide. The data showed a statistically significant extension of survival in GBM patients using the drug-device combination.

“This approval is a significant moment for newly diagnosed GBM patients in Japan,” president of the Japanese Society of Neuro-Oncology Dr. Ryo Nishikawa said. “Optune provides patients with an additional treatment option, one that has been proven to extend survival.”

“We have been eagerly anticipating this day,” Novocure’s general manager for Japan Shungo Matori added. “Newly diagnosed GBM patients have experienced an unmet need for better treatment options. We are dedicated to making Optune available to all GBM patients who can benefit from our therapy in Japan.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Regulatory/Compliance Tagged With: NovoCure

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS